Sjögren’s Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer

Tetsuo Higashi¹, Hideaki Miyamoto¹, Ryoji Yoshida², Yoki Furuta¹, Katsuya Nagaoka¹, Hideaki Naoe¹, Hisaki Naito², Hideki Nakayama² and Motohiko Tanaka¹

Abstract:
Immune checkpoint inhibitors can affect any organ, including the salivary glands. A case of Sjögren’s syndrome (SjS) induced by nivolumab for the treatment of gastric cancer is herein presented. Nivolumab treatment caused marked tumor shrinkage, but xerostomia developed after two cycles. It took 3 months after symptom onset to confirm the diagnosis of SjS. Prednisolone and pilocarpine hydrochloride did not relieve the symptoms. SjS is a relatively rare immune-related adverse event that might sometimes be overlooked. Since SjS can severely impair a patient’s quality of life, oncologists should not miss any signs of salivary gland hypofunction and cooperate with specialists for SjS.

Key words: immune-related adverse event, Sjögren’s syndrome, immune checkpoint inhibitors

(Intern Med 59: 2499-2504, 2020) (DOI: 10.2169/internalmedicine.4701-20)

Introduction
Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed death-1 (PD-1) receptor, and its ligand PD-L1 have revolutionized the treatment of various types of tumors. Although ICIs can achieve remarkable responses, their use can also cause unique immune-related adverse effects (irAEs). The notable irAEs are rash, pneumonitis, colitis, and thyroid disorders (1). ICIs can affect not only common organs, but also a variety of other organs, including the salivary glands. A case of nivolumab-induced Sjögren’s syndrome (SjS) during the treatment of gastric cancer is herein presented.

Case Report
A 60-year-old man was referred to our hospital for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric adenocarcinoma with a single liver metastasis and multiple lung metastases. He had been treated with 14 courses of capecitabine plus cisplatin with trastuzumab as the first-line chemotherapy and weekly paclitaxel (PTX) as the second-line chemotherapy. After 6 courses of weekly PTX treatment, he had undergone total gastrectomy and radiofrequency ablation (RFA) to treat the liver metastasis, because positron emission tomography-computed tomography (PET-CT) showed the disappearance of the lung metastases. Six months after surgery, CT scans showed left adrenal gland metastasis. He subsequently received irinotecan monotherapy, radiation therapy, and ramucirumab monotherapy, but the adrenal gland metastasis kept increasing in size, and multiple lung metastases also recurred (Fig. 1a).

He was treated with nivolumab as the fifth-line chemotherapy. After four cycles of nivolumab, CT showed a marked shrinkage of the lung metastases (Fig. 1b) and no change in the size of the adrenal gland metastasis. At the end of two cycles of nivolumab, xerostomia occurred. His tongue was dry and developed many fissures (Fig. 2). Since he was not taking any drugs with anticholinergic side effects and showed no findings of diabetes mellitus, his xerostomia seemed to have been caused by dehydration, and adequate daily fluid intake was thus recommended at that time. He did not have any ocular dryness symptoms and other systemic manifestations. Since the xerostomia persisted for 3

¹Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan and ²Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan
Received: February 20, 2020; Accepted: May 6, 2020; Advance Publication by J-STAGE: June 23, 2020
Correspondence to Dr. Motohiko Tanaka, mtanaka03@kumamoto-u.ac.jp
months without any improvement, salivary function tests were performed and resulted in the definitive diagnosis of SjS. The diagnosis was based on the Japanese Ministry of Health criteria for the diagnosis of SjS (Table 1) (2). We made the definite diagnosis of SjS according to the following three positive results: i) decreased salivary secretion by the Saxon test (0.3 g/2 min) and a poor uptake on salivary gland scintigraphy (Fig. 3); ii) decreased tear secretion by Schirmer’s test (right was 5 mm/5 min and left was 1 mm/5 min) and the fluorescein staining test; and iii) lymphocyte infiltration to labial salivary glands. A histopathological examination of the labial salivary gland biopsy specimens showed focal lymphocytic sialadenitis composed of both CD20+ B-cells and CD3+ T-cells with predominant T-cells. There was a predominance of CD8+ over CD4+ T cells. PD-1 and PD-L1 were both negative (Fig. 4). Serum SS-A/Ro, SS-B/La antibodies, rheumatoid factor (RF) and antinuclear antibody (ANA) were all negative.

A two-week oral treatment of prednisolone 0.5 mg/kg/day (20 mg/body) and pilocarpine hydrochloride did not improve his subjective symptoms and the salivary flow rates on the Saxon test (0.5 g/2 min). The dose of prednisolone was tapered, and was stopped one month later. A sticky feeling in the mouth and denture instability severely interfered with the patient’s dietary intake. Nivolumab was suspended after 21 courses because of persistent SjS and an exacerbation of comorbid chronic obstructive pulmonary disease. One year after the cessation of nivolumab, CT showed that the shrinkage of lung metastases was maintained (Fig. 1c, d), and the adrenal gland metastasis remained unchanged in size. At that time, there was no improvement in both his subjective symptoms and salivary flow rates on the Saxon test (0.1 g/2

Figure 1. Computed tomography (a) before treatment with nivolumab, (b) after 7 cycles of nivolumab treatment, (c) after 15 cycles of nivolumab treatment, and (d) 1 year after the cessation of nivolumab treatment.

Figure 2. Oral cavity. The patient shows significant papillary atrophy with erythema and fissuring of the dorsum of the tongue. A fissured tongue is a benign condition characterized by deep grooves (fissures) in the dorsum of the tongue. Dry mouth may cause fissured tongue.
Table 1. The Revised Japanese Ministry of Health Criteria for the Diagnosis of SjS (2).

| Oral examination | Definition: Positive for at least one of (A) or (B):  
|                 | A) Abnormal findings in sialography≥Stage I (diffuse punctate shadows of less than 1mm)  
|                 | B) Decreased salivary secretion (flow rates<10mL/10min according to the chewing gum test or ≤2g/2min according to the Saxon test) and decreased salivary function according to salivary gland scintigraphy |

| Ocular examination | Definition: Positive for at least one of (A) or (B):  
|                   | A) Schirmer’s test≤5mm/5min and rose bengal test≥3 according to the van Bijsterveld score  
|                   | B) Schirmer’s test≤5mm/5min and positive fluorescein staining test |

| Histopathology | Definition: Positive for at least one of (A) or (B):  
|                | A) Focus score≥1 (periductal lymphoid cell infiltration≥50) in a 4-mm² minor salivary gland biopsy  
|                | B) Focus score≥1 (periductal lymphoid cell infiltration≥50) in a 4-mm² lacrimal gland biopsy |

| Serological examination | Definition: Positive for at least one of (A) or (B):  
|                       | A) Anti-Ro/SS-A antibody  
|                       | B) Anti-La/SS-B antibody |

| Diagnostic criteria | Diagnosis of Sjögren’s syndrome can be made when the patient meets at least two of the above four criteria |

The underlined items were matched for this case.

Discussion

A case of SjS caused by nivolumab as a fifth-line chemotherapy for gastric cancer is herein described. Nivolumab achieved marked tumor shrinkage, but it induced xerostomia at the end of two cycles. The diagnosis of SjS as an irAE was confirmed 3 months after the onset of symptoms. Though prednisolone and pilocarpine hydrochloride were administered, they resulted in little symptomatic improvement.

Cases of ICI-induced sicca syndrome were first reported in four (0.5%) of 700 patients treated with nivolumab and/or ipilimumab (3). There have been nine case reports or case series of sicca syndrome caused by any ICI class in various types of cancer, which are summarized in Table 2 (3-11). They were mainly treated with corticosteroids, resulting in an improvement of symptoms in 74% (57/77) of them with various antitumor effects. In detail, Burel et al. reported that the prevalence of SjS was 0.3% with anti-PD-1/anti-PD-L1 agents alone and 2.5% with a combination of anti-PD-1 and anti-CTLA4 agents (6). Since xerostomia could occur in various settings, such as dehydration, hyperglycemia, or as...
side effects of anticholinergic drugs, ICI-induced sicca syndrome/SjS can sometimes easily be overlooked, and its prevalence may thus be underestimated.

Ramos-Casals et al. identified 26 cases of sicca syndrome/SjS triggered by ICIs in patients with cancer in the data from the International ImmunoCancer Registry (ICIR) (9). Among them, the cases that conformed to the criteria of SjS-induced ICIs had a very specific clinical profile, different from that observed in idiopathic SjS, with half of the cases being men, a lower frequency of positive SS-A/B antibodies, an older age, and a lower frequency of ocular dryness, compared to idiopathic primary SjS. Warner et al. reported 20 patients with new or worsening xerostomia on ICI treatment (10). The histopathological features of labial salivary gland biopsy consisted of mild chronic sialadenitis or focal lymphocytic sialadenitis, with infiltrating cells being predominantly T-lymphocytes and few B cells. This pattern was different from the characteristic idiopathic primary SjS in which B cells account for 20-62% of all infiltrating lymphocytes (12). Though the mechanism of sicca syndrome/SjS caused by immunotherapy has not yet been elucidated, the results of these previous studies suggest that an impairment of the PD-1/PD-L1 pathway caused by ICIs triggers the activation of T-lymphocytes, leading to infiltration of the salivary gland epithelium. In the present case, it was speculated that ICI induced SjS based on negative results of serum SS-A/Ro, SS-B/La antibodies and absence of other laboratory abnormalities suggesting primary SjS, although a histological examination of labial salivary gland showed a certain amount of B-cell infiltration in all lymphocytes, which was inconsistent with the previous report.

For the management of irAEs, corticosteroids are used according to current practical treatment algorithms (1). Ramos-Casals et al. reported that, in most cases, sicca symptoms were managed with topical measures including pilocarpine and cyclosporine A drops, but which failed to relieve the symptoms in our case (9). Warner et al. reported that subjective improvement in symptoms was achieved in the majority of cases by ICI cessation with or without corticosteroid administration (10); however, few patients regained normal salivary flow rates.

In the present case, prednisolone 20 mg per day and pilocarpine hydrochloride were administered, which did not improve either the subjective symptoms or the salivary flow rates. The poor response to the drugs may have been caused by the continuous administration of nivolumab for 3 months.
Table 2. Reported Cases of Sicca / Sjögren’s Syndrome Induced by ICIs.

| Reference | No. of cases* | Type of malignancy | n | ICI† | n | Time to onset (weeks) | ANA‡ | Anti-SSA and/or SSB§ | Treatment | Improvement of sicca syndrome | Antitumor effect |
|-----------|--------------|------------------|---|------|---|----------------------|------|---------------------|----------|-----------------------------|-----------------|
| (3) 4     | Melanoma     | 3 Nivolumab      | 2 | 8-32 | 3/4 | Prednisone           | 3    | 3/4                | PR       | 1                           |
|           | NSCLCII      | 1 Ipilimumab     | 1 |       |     | Piilocarpine         | 1    | SD                 |          | 2                           |
|           |              | Nivolumab and Ipilimumab | 1 |       |     | Cevimeline           | 2    | PD                 |          | 1                           |
| (4) 5     | Melanoma     | 4 Nivolumab and Ipilimumab | 3 | 2-22 | 2/5 | Prednisone           | 5    | 5/5                | N/A      |                             |
|           | Renal cell carcinoma | 1 Nivolumab | 1 |       |     | Piilocarpine         | 1    | SD                 | 1        |                             |
|           |              | Atezolizumab     | 1 |       |     | Artificial saliva    | 1    |                    |          |                             |
| (5) 1     | Parotid acinic cell carcinoma | 1 Pembrolizumab | 1 | 33   | 0  | Prednisone           | 1    | 1/1                | SD       | 1                           |
| (6) 3     | Renal cell carcinoma | 1 Anti-PD-1 and Anti-CTLA-4 | 1 | 8-11 | 3/3 | Prednisone           | 1    | 3/3                | PR       | 2                           |
|           | Cervical squamous cell carcinoma | 1 Anti-PD-L1BRAF and MEK inhibitors | 1 |       |     | Piilocarpine         | 1    | SD                 |          | 1                           |
|           | Melanoma     | 1 Anti-PD-1 and Anti-CTLA-4 | 1 |       |     | Cevimeline           | 1    |                  |          |                             |
|           |              | Melanoma         | 1 |       |     | CyA drops            | 1    |                    |          |                             |
| (7) 1     | NSCLCII      | 1 Nivolumab      | 1 | 16   | 0  | Prednisone           | 1    | 1/1                | N/A      |                             |
| (8) 2     | NSCLCII      | 1 Nivolumab      | 2 | 15, 24 | 2/2 | Corticosteroids      | 1    | 2/2                | N/A      |                             |
|           | Pancreatic neuroendocrine cancer | 2 Pembrolizumab | 1 |       |     | Piilocarpine         | 2    |                    |          |                             |
| (9) 26    | Lung cancer  | 12 Nivolumab     | 9 | 4-112 | 13/26 | Corticosteroids     | 2    | 23/26              | N/A      |                             |
|           | Renal cancer | 7 Pembrolizumab  | 7 |       |     | Piilocarpine         | 2    |                    |          |                             |
|           | Melanoma     | 4 Durvalumab     | 4 |       |     | Cevimeline           | 1    |                    |          |                             |
|           | Colon cancer | 1 Nivolumab and Ipilimumab | 5 |       |     | CyA drops            | 1    |                    |          |                             |
|           | Chordoma     | 1 Nivolumab and pegIL10 | 1 |       |     |                    | 1    |                    |          |                             |
|           | Cervical cancer | 1 Nivolumab | 1 |       |     |                    | 1    |                    |          |                             |
| (10) 20   | Melanoma     | 10 Nivolumab     | 5 | 4-30 | 3/20 | Prednisone          | 10   | 9/20               | CR       | 3                           |
|           | Respiratory papillomatosis | 4 Avelumab | 8 |       |     | Piilocarpine         | 2    |                    |          |                             |
|           | Thymic carcinoma | 3 Pembrolizumab | 3 |       |     | Cevimeline           | 8    |                    |          |                             |
|           | NSCLCII      | 1 Nivolumab and Ipilimumab | 2 |       |     | CyA drops            | 3    |                    |          |                             |
|           | Prostate cancer | 1 Pembrolizumab and Ipilimumab | 1 |       |     |                    | 3    |                    |          |                             |
|           | Gastroesophageal junction adenocarcinoma | 1 Anti-PD-L1 and TGF-beta | 1 |       |     |                    | 1    |                    |          |                             |
|           |                | Nivolumab        | 1 |       |     |                    | 1    |                    |          |                             |
| (11) 15   | Melanoma     | 6 Anti-PD1       | 7 | 2-68 | not assessed | 1/15 | Corticosteroids     | 10      | PR                           |
|           | Oral squamous cell carcinoma | 3 Anti-PDL1 | 1 |       |     | 15/15               | PR   |                    |          |                             |
|           | Renal cancer | 2 Anti-PD-1 and Anti-CTLA-4 | 3 |       |     | Symptomatic measures§ | 13    |                    |          |                             |
|           | Endometrial adenocarcinoma | 2 Anti-PD-1 and ICI under development | 4 |       |     |                    | 1    |                    |          |                             |
|           | Pancreatic adenocarcinoma | 1 |       |     |                    | 1    |                    |          |                             |
|           | NSCLCII      | 1 Nivolumab      | 1 | 4    | 0  | Corticosteroids     | 1    | 0                  | PR       | 1                           |

* Number of sicca / Sjögren’s syndrome cases, † Immune checkpoint inhibitor, ‡ Numerator shows positive cases for antinuclear antibody, § Numerator shows positive cases for anti-SSA and/or SSB, ¶ non-small cell lung carcinoma, §§Symptomatic measures: hydration, gum, oral hygiene, anetholtrithon/piilocarpine, salivary substitute
after the onset of symptoms due to the delay in diagnosis.

Although sicca syndrome/SjS itself is not a fatal irAE, xerostomia can cause dysgeusia, interfere with the oral intake, and significantly reduce a patients’ quality of life (13). In addition, long-term salivary gland hypofunction can increase the risk of carious teeth, periodontitis, and denture instability. In the present case, denture instability significantly disturbed the patient’s dietary intake. Decreased salivary secretion may imply the early phase of SjS, even if the case does not satisfy the current diagnostic criteria for SjS. It is important for oncologists to cooperate with various specialists including ophthalmologists, otolaryngologists and rheumatologists when the patients show sicca syndrome/SjS.

In the present case, nivolumab had a marked therapeutic effect and maintained tumor shrinkage for one year after its cessation. Some studies have shown that the development of irAEs was associated with the therapeutic outcome of ICI (14, 15). It remains uncertain whether sicca syndrome/SjS can be a positive predictive marker of the therapeutic outcome, though the therapeutic response may have correlated with salivary gland dysfunction in the present case. The salivary gland function is measurable with non-invasive methods such as the Saxon test and the gum test. Additional studies are needed to investigate the relationship between decreased salivary secretion and a good therapeutic outcome.

**Conclusion**

A case of SjS caused by nivolumab for gastric cancer was described. Since sicca syndrome/SjS impairs a patients’ quality of life, oncologists should be careful not to miss any signs of salivary gland hypofunction and then cooperate with specialists of various fields including ophthalmology, otolaryngology and rheumatology.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: iv119-iv142, 2017.
2. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol 14: 425-434, 2004.
3. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76: 43-50, 2017.
4. Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese L.H. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3: e000412, 2017.
5. Teyssonave D, Cousin S, Italiano A. Gougerot-Sjögren-like syndrome under PD-1 inhibitor treatment. Ann Oncol 28: 3108, 2017.
6. Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82: 34-44, 2017.
7. Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M. Nivolumab-induced sialadenitis. Respiril Case Rep 6: e00322, 2018.
8. Narváez J, Juarez-Lopez P, LLuch J, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17: 1040-1045, 2018.
9. Ramos-Casals M, Maria A, Suarez-Almazor ME, et al. Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol 37 (Suppl 118): 114-122, 2019.
10. Warner BM, Baer AN, Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24: 1259-1269, 2019.
11. Ortiz Brugués A, Sibaud V, Herbault-Barres B, et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist 25: e391-e395, 2020.
12. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun 34: 400-407, 2010.
13. Jensen SB, Pedersen AM, Vissink A, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18: 1039-1060, 2010.
14. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22: 886-894, 2016.
15. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4: 374-378, 2018.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).